Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Testing ivonescimab in combination with standard chemotherapy in advanced or metastatic gastric and gastroesophageal adenocarcinoma patients Recruiting

2025-520694-39-00 Metastatic or locally advanced irresectable (stage IV) 4 2025-10-24
A Study of LY4175408 in Participants With Advanced or Metastatic Solid Tumors. Recruiting

2025-521916-20-00 Cancer 1 2025-10-24
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antim… Recruiting

2024-517140-65-00 Multiple Myeloma (MM). 9 2025-10-23
Neoadjuvant Cemiplimab Plus Imiquimod in Cutaneous Basal Cell Carcinoma. Recruiting

2025-520698-38-00 Cutaneous Basal Cell Carcinoma 9 2025-10-22
Durvalumab and tremelimumab with or without Hepatic Arterial Infusion of gemcitabine and oxaliplatin in hepatocellular carcinoma patients. Recruiting

2024-514912-28-00 Patients with hepatocellular carcinoma with high tumor 10 2025-10-22
A study to evaluate dosing schedules of mirvetuximab soravtansine in patients with epithelial ovarian, primary peritoneal, or fallopian tube… Recruiting

2024-517184-23-00 platinum-resistant advanced high-grade epithelial ovari 4 2025-10-16
Influence des caractéristiques morphologiques sur la pharmacocinétique et la toxicité du trastuzumab-déruxtécan chez des patients ayant un c… Recruiting

2025-522656-68-00 Metastatic breast cancers 6 2025-10-15
A clinical study of patritumab deruxtecan in people with breast cancer Recruiting

2024-514376-40-00 High Risk Early-Stage Triple Negative Breast Cancer (TN 4 2025-10-15
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell… Recruiting

2024-516234-35-00 Relapsed or Refractory B-Cell Malignancies 9 2025-10-15
Hepatic radiotherapy added to standard of care for the treatment of HLA A*02:01 positive Metastatic Uveal Melanoma patients Recruiting

2024-519760-40-00 metastatic uveal melanoma HLA A*02:01 positive 4 2025-10-14
A Phase 1/2, Multicenter, Open Label, Dose Escalation and Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients with Unre… Recruiting

2024-512421-92-00 Unresectable, Locally Advanced or Metastatic Cancer 7 2025-10-14
Phase Ib-II, non-randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with modFOLFIRINOX for front-line trea… Recruiting

2024-511459-16-00 Histologically confirmed pancreatic adenocarcinoma with 9 2025-10-14
Clinical trial comparing induction treatment with EGFR-ADC MRG003 alone or in combination with the anti PD1 Pucotenlimab, followed by radioc… Recruiting

2023-510558-18-00 locally advanced head and neck squamous cell carcinoma 4 2025-10-13
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of NSCLC Recruiting

2024-519883-42-00 Non-small cell lung cancer 5 2025-10-08
An open-label study of JSB462 (luxdegalutamide) in combination with abiraterone in adult male patients with metastatic hormone-sensitive pro… Recruiting

2024-520156-22-00 Metastatic hormone-sensitive prostate cancer 4 2025-10-08
Randomized phase III trial of sequential Re-Radiochemotherapy and Pembrolizumab versus Immuno(chemo)therapy for locoregionally recurrent PD-… Recruiting

2024-520264-33-00 Locoregionally recurrent head and neck squamous cell ca 5 2025-10-07
A Phase 1/1b Study of IAM1363 in HER2 Cancers Recruiting

2024-519188-17-00 Relapsed/refractory malignancy with documented diagnosi 1 2025-10-07
Long-term follow-up of patients treated with GD2IL18CART Recruiting

2025-521497-34-00 Neuroblastoma 1 2025-10-06
A Study to Test How Safe, Effective and How Body’s Responds to the Combination of Mosunetuzumab and Pirtobrutinib Together to Treat Patients… Recruiting

2024-514152-32-00 Relapsed or Refractory Chronic Lymphocytic Leukemia (R/ 3 2025-10-06
SAFE-ESO_Phase II study evaluating safety and efficacy of Tislelizumab for elderly patients unfit for chemotherapy, with advanced esophageal… Recruiting

2024-518358-17-00 Squamous cell carcinoma of the esophagus 4 2025-10-06
A study to test a new immunotherapy, ABX-001, alone and in combination with the marketed drug, pembrolizumab, for the treatment of tumors pr… Recruiting

2024-512403-39-01 Advanced Solid Tumors Who Are Beyond Standard of Care 1 2025-10-03
A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel Recruiting

2025-521975-30-00 Newly Diagnosed Multiple Myeloma 4 2025-10-03
Efficacy and safety of trifluridin/tipiracil in combination with nanoliposomal irinotecan as a second line therapy in patients with cholangi… Recruiting

2024-517330-18-00 advanced, non resectable or metastatic cholangio- or ga 4 2025-10-02
Dose Escalation and Dose Expansion Study of BBO-10203 in Subjects with Advanced Solid Tumors Recruiting

2024-519445-29-00 Solid Tumors 1 2025-10-02